RNA Analytical/Quality Videos

31. Circular RNA Process Development: A Quick Primer 10/15/2025

    In this Advancing RNA Live clip, Sail Biomedicines’ Marc Wolfgang gives us a brief primer on the main differences and challenges in developing an IVT reaction for circular RNA, as opposed to linear mRNA.    

32. What Does 2025 (And Beyond) Hold For The RNA-LNP Space? 12/4/2024

    Three LNP experts share their thoughts on the incremental advancements they’d like to see the RNA-LNP space make in the next few years.

33. Strategies To De-Risk Next-Gen mRNA Raw Materials 12/3/2025

    In this Advancing RNA Live clip, Khaled Yamout and Sanofi’s Francoise Ribes share the quality considerations that are top of mind when evaluating a novel raw material, as well as how the broader industry (i.e., standard setting organizations, suppliers, and biotechs) can arrive at a clearer understanding of a material’s quality.

34. A&M STABTEST Shares QC Analysis Of Oligo Therapeutics 9/20/2022

    Explore best practices for developing a QC method for identification and impurity analysis of oligonucleotides, as well as tips on mitigating risk by using compliant instrumentation and software.

35. How "Successful" Are Our mRNA-LNP Outsourcing Partnerships Today? 2/10/2025

    In this snippet, panelist Alex Aust (with the help of several live attendee commenters) tackles a particularly tricky question: Are our outsourcing partnerships producing high quality products today, and what are the most common root causes of batch failures?

36. What Learnings Can mRNA Take From The Oligonucleotide Regulatory Paradigm? 5/10/2024

    ReciBioPharm’s Melanie Cerullo shares where mRNA needs to “catch up” to its oligonucleotide “cousin” molecules and where regulatory differences may be emerging between modalities.

37. Must-Have CDMO Capabilities And MSA Make-Or-Breaks For mRNA-LNP Outsourcing 2/10/2025

    Three Advancing RNA Live panelists share their greatest needs in outsourcing partnerships for mRNA/RNA-LNP products and where sponsors should be the most prescriptive when drafting an MSA with an outsourcing partner.

38. The Evolutions Of mRNA Analytical Development (So Far) 8/22/2024

    Linear mRNA analytical development has been rapidly advancing in the past few years and this panel discussion explores some of the biggest changes we’ve seen in the linear mRNA analytical paradigm.

39. Where Does The mRNA Vaccine Regulatory Paradigm Fall Short For Therapeutics? 5/10/2024

    This Advancing RNA panel of experts sees a couple of important questions those striving to make RNA therapeutics will find themselves confronting when collaborating with regulators.

40. Your Roadmap For Efficient Processes 3/4/2025

    Struggling with mRNA integrity? Discover essential strategies to boost stability in mRNA manufacturing with innovative endonuclease-free DTT and Spermidine chemicals.